At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 21 enrolled
Drug / intervention
Intravenous (IV) zanamivirdrug
Likely dose
Intravenous (IV) zanamivir 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-centre, Single Arm Study to Evaluate the Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Confirmed Influenza Infection (NAI115215)
In Brief
A Phase 3 clinical trial evaluating Intravenous (IV) zanamivir for Influenza, Human. Completed, enrolled 21 participants across 7 sites.
Detailed Summary
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedFeb 2012
Primary CompletionMar 2013
Study CompletionMar 2013
TodayJul 2026
First PostedFeb 6, 2012
Enrollment StartJan 1, 2012
Primary CompletionMar 1, 2013
Study CompletionMar 29, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.4 years ago
Interventions
Intravenous (IV) zanamivirdrug
Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days